Seoul, South Korea – Mocuis Co., Ltd., has partnered with IL-Yang Pharmaceutical Co. Ltd. for the exclusive out-licensing of Supect ® (radotinib hydrochloride). Supect is a second generation tyrosine kinase inhibitor approved in South Korea for the treatment of patients with Philadelphia positive chronic myeloid leukemia (Ph+ CML) without optimal response and/or tolerance to other Bcr-Abl tyrosine kinase inhibitors. The product is currently in a multi-country Phase III clinical trial to assess its efficacy and safety in treating newly diagnosed CML patients as first-line therapy.
Jenny (Seungyun) Jo, CEO of Mocuis, stated, “Because of the emergence of resistance and intolerance to the first tyrosine kinase inhibitor, there is a constant need to develop novel products to treat Ph+ CML that are both effective and safe. IL-YANG developed radotinib HCl and introduced it in the South Korean market where it is co-marketed with Daewoong Pharmaceuticals. IL-Yang now seeks to have the product made available to treat Ph+ CML patients in all countries of the world.”
About Mocuis Co., Ltd.
Located in Seoul, South Korea and Chicago, Illinois, Mocuis (mō’kĭs), is a specialty firm that partners and advises clients with a cross-functional approach in order to maximize asset and stakeholder value. We focus on quality businesses with leading positions in areas such as, biotech, pharmaceutical, technology, real estate, and manufacturing. Mocuis specializes in global strategy, market preparedness, alliance management, business development, marketing, funding and M&A. Visit www.mocuis.com for more information.
About IL-YANG Pharmaceutical Co., Ltd.
Founded in 1946, IL-Yang Pharmaceutical Co., Ltd. is one of the leading Korean pharmaceutical companies focusing on developing new chemical entities. The current pipeline includes novel compounds in the fields of oncology, autoimmune, anti-viral, and myocardial infarction. The company also produces a broad range of primary care and specialty pharmaceuticals, nutritionals and cosmetics for the Korean market. Visit www.ilyang.co.kr/english for more information.